TY - JOUR
T1 - Semaphorin 4B is an ADAM17-cleaved adipokine that inhibits adipocyte differentiation and thermogenesis
AU - Amin, Abdulbasit
AU - Badenes, Marina
AU - Tüshaus, Johanna
AU - de Carvalho, Érika
AU - Burbridge, Emma
AU - Faísca, Pedro
AU - Trávníčková, Květa
AU - Barros, André
AU - Carobbio, Stefania
AU - Domingos, Pedro M.
AU - Vidal-Puig, Antonio
AU - Moita, Luís F.
AU - Maguire, Sarah
AU - Stříšovský, Kvido
AU - Ortega, Francisco J.
AU - Fernández-Real, José Manuel
AU - Lichtenthaler, Stefan F.
AU - Adrain, Colin
N1 - Funding Information:
The authors thank the anonymous reviewers whose insightful and constructive critiques have helped to improve our manuscript. We thank the Ethics Committee, Animal Facility, Histopathology and Flow cytometry units and the Antibody Service of the Instituto Gulbenkian de Ciência. We thank Hana Dvořáková and Zuzana Vaitová for assistance with production of recombinant Semaphorin 4B. We thank Andreas Püschel for the Sema4b expression plasmid. We acknowledge the support of Fundação Calouste Gulbenkian; Queen's University Belfast; Worldwide Cancer Research ( 14–1289 ); a Marie Curie Career Integration Grant (project no. 618769 ); Fundação para a Ciência e Tecnologica (FCT) grants, SFRH/BCC/52507/2014 , PTDC/BEX-BCM/3015/2014 and LISBOA-01–0145-FEDER-031330 ), funding from ‘La Caixa’ Foundation under the agreement ; support from the ERDF / ESF project ChemBioDrug (No. CZ.02.1.01/0.0/0.0/16_019/0000729 ) and by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy–ID 390857198). This work was developed with the support of the research infrastructure Congento, project LISBOA-01–0145-FEDER-022170, co-financed by Lisboa Regional Operational Programme (Lisboa 2020), under the Portugal 2020 Partnership Agreement, through the European Regional Development Fund ( ERDF ), and Foundation for Science and Technology (Portugal) . This study was supported by research grants from the Government of Catalonia , Spain ( SGR 2021/01263 ) and of the Instituto de Salud Carlos III (ISCIII) through the projects PI18/01022 and PI21/01361 (Cofounded by European Regional Development Fund (ERDF) “a way to build Europe” and by the European Social Fund ( ESF ), “investing in your future”), by the Fondo Europeo de Desarrollo Regional ( FEDER ), and the CIBER de la Fisiopatología de la Obesidad y la Nutrición ( CIBEROBN ), also an initiative ISCIII . We want to acknowledge the kind collaboration of all of the participants involved in this study, the FATBANK platform (also promoted by the CIBEROBN), and the Biobanc (B.0000872) of the Institut d’Investigació Biomèdica de Girona (IDIBGI), integrated in the Spanish National Biobanks Network. FJO (MS19/00109) is recipient of the Miguel Servet scheme; Ministerio de Ciencia, Innovación y Universidades, Gobierno de España (ES).
Funding Information:
To better understand the impact of tSema4B on adipocyte biology in general and specifically to elucidate how tSema4B perturbed processes required to support thermogenesis, we performed RNAseq on WT immortalized primary adipocytes overexpressing tSema4B or the empty vector, under unstimulated (Fig. 7G) versus NE-stimulated conditions (Fig. 7H). Under unstimulated conditions, when a threshold of a log2 fold change of at least 1 or -1 was applied, 543 and 732 genes were upregulated and downregulated (Fig. 7G). Notably, the cohort of genes that were upregulated by tSema4B included Nrp1 (a semaphorin co-receptor that has been reported to bind to Sema4B) plus genes associated with remodeling of the extracellular matrix (Col1a; Fbln1, Fbln2, Timp1). The latter genes, which are expressed at higher levels in fibroblastoid cells such as preadipocytes could indicate that tSema4B impairs adipogenesis. By contrast, prominently downregulated hits were genes involved in lipid metabolism and fatty acid update such Lpl (lipoprotein lipase) the fatty acid transporter CD36 and the fatty acid binding protein Fabp4 and lipolysis (Atgl/Pnpla2). As anticipated from the qPCR studies, we also observed downregulation of genes associated with BAT thermogenesis (Pparγ, Ucp1). The latter downregulated genes could suggest that Sema4B impairs adipogenesis, curtailing the expression of lipolytic and thermogenic genes.The authors thank the anonymous reviewers whose insightful and constructive critiques have helped to improve our manuscript. We thank the Ethics Committee, Animal Facility, Histopathology and Flow cytometry units and the Antibody Service of the Instituto Gulbenkian de Ciência. We thank Hana Dvořáková and Zuzana Vaitová for assistance with production of recombinant Semaphorin 4B. We thank Andreas Püschel for the Sema4b expression plasmid. We acknowledge the support of Fundação Calouste Gulbenkian; Queen's University Belfast; Worldwide Cancer Research (14–1289); a Marie Curie Career Integration Grant (project no. 618769); Fundação para a Ciência e Tecnologica (FCT) grants, SFRH/BCC/52507/2014, PTDC/BEX-BCM/3015/2014 and LISBOA-01–0145-FEDER-031330), funding from ‘La Caixa’ Foundation under the agreement < LCF/PR/HR17/52150018>; support from the ERDF/ESF project ChemBioDrug (No. CZ.02.1.01/0.0/0.0/16_019/0000729) and by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy–ID 390857198). This work was developed with the support of the research infrastructure Congento, project LISBOA-01–0145-FEDER-022170, co-financed by Lisboa Regional Operational Programme (Lisboa 2020), under the Portugal 2020 Partnership Agreement, through the European Regional Development Fund (ERDF), and Foundation for Science and Technology (Portugal). This study was supported by research grants from the Government of Catalonia, Spain (SGR 2021/01263) and of the Instituto de Salud Carlos III (ISCIII) through the projects PI18/01022 and PI21/01361 (Cofounded by European Regional Development Fund (ERDF) “a way to build Europe” and by the European Social Fund (ESF), “investing in your future”), by the Fondo Europeo de Desarrollo Regional (FEDER), and the CIBER de la Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), also an initiative ISCIII. We want to acknowledge the kind collaboration of all of the participants involved in this study, the FATBANK platform (also promoted by the CIBEROBN), and the Biobanc (B.0000872) of the Institut d'Investigació Biomèdica de Girona (IDIBGI), integrated in the Spanish National Biobanks Network. FJO (MS19/00109) is recipient of the Miguel Servet scheme; Ministerio de Ciencia, Innovación y Universidades, Gobierno de España (ES).
Publisher Copyright:
© 2023 The Authors
PY - 2023/7
Y1 - 2023/7
N2 - Objective: The metalloprotease ADAM17 (also called TACE) plays fundamental roles in homeostasis by shedding key signaling molecules from the cell surface. Although its importance for the immune system and epithelial tissues is well-documented, little is known about the role of ADAM17 in metabolic homeostasis. The purpose of this study was to determine the impact of ADAM17 expression, specifically in adipose tissues, on metabolic homeostasis. Methods: We used histopathology, molecular, proteomic, transcriptomic, in vivo integrative physiological and ex vivo biochemical approaches to determine the impact of adipose tissue-specific deletion of ADAM17 upon adipocyte and whole organism metabolic physiology. Results: ADAM17adipoq-creΔ/Δ mice exhibited a hypermetabolic phenotype characterized by elevated energy consumption and increased levels of adipocyte thermogenic gene expression. On a high fat diet, these mice were more thermogenic, while exhibiting elevated expression levels of genes associated with lipid oxidation and lipolysis. This hypermetabolic phenotype protected mutant mice from obesogenic challenge, limiting weight gain, hepatosteatosis and insulin resistance. Activation of beta-adrenoceptors by the neurotransmitter norepinephrine, a key regulator of adipocyte physiology, triggered the shedding of ADAM17 substrates, and regulated ADAM17 expression at the mRNA and protein levels, hence identifying a functional connection between thermogenic licensing and the regulation of ADAM17. Proteomic studies identified Semaphorin 4B (SEMA4B), as a novel ADAM17-shed adipokine, whose expression is regulated by physiological thermogenic cues, that acts to inhibit adipocyte differentiation and dampen thermogenic responses in adipocytes. Transcriptomic data showed that cleaved SEMA4B acts in an autocrine manner in brown adipocytes to repress the expression of genes involved in adipogenesis, thermogenesis, and lipid uptake, storage and catabolism. Conclusions: Our findings identify a novel ADAM17-dependent axis, regulated by beta-adrenoceptors and mediated by the ADAM17-cleaved form of SEMA4B, that modulates energy balance in adipocytes by inhibiting adipocyte differentiation, thermogenesis and lipid catabolism.
AB - Objective: The metalloprotease ADAM17 (also called TACE) plays fundamental roles in homeostasis by shedding key signaling molecules from the cell surface. Although its importance for the immune system and epithelial tissues is well-documented, little is known about the role of ADAM17 in metabolic homeostasis. The purpose of this study was to determine the impact of ADAM17 expression, specifically in adipose tissues, on metabolic homeostasis. Methods: We used histopathology, molecular, proteomic, transcriptomic, in vivo integrative physiological and ex vivo biochemical approaches to determine the impact of adipose tissue-specific deletion of ADAM17 upon adipocyte and whole organism metabolic physiology. Results: ADAM17adipoq-creΔ/Δ mice exhibited a hypermetabolic phenotype characterized by elevated energy consumption and increased levels of adipocyte thermogenic gene expression. On a high fat diet, these mice were more thermogenic, while exhibiting elevated expression levels of genes associated with lipid oxidation and lipolysis. This hypermetabolic phenotype protected mutant mice from obesogenic challenge, limiting weight gain, hepatosteatosis and insulin resistance. Activation of beta-adrenoceptors by the neurotransmitter norepinephrine, a key regulator of adipocyte physiology, triggered the shedding of ADAM17 substrates, and regulated ADAM17 expression at the mRNA and protein levels, hence identifying a functional connection between thermogenic licensing and the regulation of ADAM17. Proteomic studies identified Semaphorin 4B (SEMA4B), as a novel ADAM17-shed adipokine, whose expression is regulated by physiological thermogenic cues, that acts to inhibit adipocyte differentiation and dampen thermogenic responses in adipocytes. Transcriptomic data showed that cleaved SEMA4B acts in an autocrine manner in brown adipocytes to repress the expression of genes involved in adipogenesis, thermogenesis, and lipid uptake, storage and catabolism. Conclusions: Our findings identify a novel ADAM17-dependent axis, regulated by beta-adrenoceptors and mediated by the ADAM17-cleaved form of SEMA4B, that modulates energy balance in adipocytes by inhibiting adipocyte differentiation, thermogenesis and lipid catabolism.
KW - ADAM17/TACE
KW - Adipose tissue
KW - Beta-adrenoceptor signalling
KW - Cold challenge
KW - Metabolism
KW - Obesity
KW - Semaphorin4B Sema4b
KW - Thermogenesis
UR - http://www.scopus.com/inward/record.url?scp=85159048866&partnerID=8YFLogxK
U2 - 10.1016/j.molmet.2023.101731
DO - 10.1016/j.molmet.2023.101731
M3 - Article
C2 - 37121509
AN - SCOPUS:85159048866
SN - 2212-8778
VL - 73
JO - Molecular Metabolism
JF - Molecular Metabolism
M1 - 101731
ER -